Objective-To determine the relative risk of developing endometrial neoplasia after treatment with oestrogens alone or in conjunction with progestogens.
confounding factors were identified.
Measurements-The total number of person years was divided into exposure groups by inference from the data from the questionnaire. Compensation was made for the excess of hysterectomies. Specimens from all cases of endometrial neoplasia in the cohort and 90% of cases in the general population were studied blind histopathologically. Characteristics of treatment of all women who had endometrial neoplasia were assessed by questionnaire. Relative risks and 95% confidence intervals were calculated.
Results-Seventy four cases of carcinoma and 33 cases of premalignant lesions occurred in the cohort. The relative risk of endometrial carcinoma was [1] [2] [3] [4] [5] [6] [7] [8] (95% confidence interval 11 to 3-2) after exposure to any oestrogen compound without progestogen for more than six years; 2-2 (1-2 to 4.4) after more than three years' exposure to conjugated oestrogens without progestogen; and [2] [3] [4] [5] [6] [7] (1-4 to 5-1) after more than three years' exposure to oestradiol compounds without progestogen. When carcinoma and premalignant lesions were considered together the results were similar but the relative risk was higher. Risk of carcinoma did not increase when progestogens were cyclically added to oestrogens for the entire treatment period (relative risk 0-9 (0.4 to 2-0)).
Introduction
Case-control studies have provided evidence of an increase in the risk of developing endometrial cancer dependent on the dose and duration of exposure to conjugated oestrogens without concomitant use of progestogens.' The wide variation in estimates of overall risk, which range from a twofold to a 12-fold increase, has been attributed to differences in methodology, including the histopathological criteria of cancer used, selection of cases and controls, definition of exposure, and dose and duration of treatment. ' Although the validity of the results of these retrospective studies has been debated,2 a true, causal association is considered to exist. ' Progestogens added for at least 10 days of each treatment cycle have been shown to protect against endometrial hyperplasia,4 and a combined regimen is now commonly used to treat women who have not had their uterus removed. Epidemiological data have been too scarce to show whether adding progestogens can prevent endometrial cancers after long term treatment.
We report the results of the first six years of a large prospective investigation of a population based cohort that was designed to analyse the risk of endometrial cancer with special regard to duration and type of exposure to oestrogen and to the presence of added progestogens. It is the first epidemiological study of sufficient size to evaluate the effects of the combined regimen of oestrogens and progestogens on risk of cancer and to use an unbiased histopathological classification of all cases of cancer.
Methods
The case-cohort approach was used for this investigation.6 A large cohort of women who had been prescribed non-contraceptive oestrogens for menopausal problems was defined by information from their prescription forms. A person vears was necessary." Thus a follow up of more than three years would be expected to yield a cohort of adequate size to show this increase in risk.
A pilot study showed that the pharmacies reported 95% of all prescriptions. About 77000 prescriptions were identified. Two sets of data were taken from the prescription forms: the national registration number was used to identify and follow up each woman, and data on the type of oestrogen, dose and frequency of administration, and date of purchase were used to characterise each exposure to oestrogen.
The cohort finally comprised 23 244 women who had had one or more prescriptions for drugs containing oestrogen during April 1977 to March 1980, were aged 35 or older when they bought the first recorded prescription, and lived in the defined region." The national registration numbers of all subjects were matched with those of all women newly diagnosed as having cancer or premalignancy of the endometrium, identified from the cancer registry of the Uppsala health care region. In this way all cases in the cohort within the region were ascertained. DETERMINAT The starting point of observation of all cohort members was the purchase date of the first reported prescription, and the end point was the date of death, dated diagnosis of a premalignant lesion or cancer, or December 1983. The numbers of person years were calculated according to duration of exposure, type of oestrogen compounds, and presence of progestogen by inference from proportions found in the sample given the questionnaires. Changes in exposure classification as follow up continued were calculated with the occupational cohort mortality program (OCMAP).' Patients with endometrial neoplasia and person years were divided into five exposure groups: oestrogen only, oestrogen taken solely in conjunction with progestogen, oestrogen with progestogen preceded by less than five years of oestrogen alone, oestrogen with progestogen preceded by more than five years of oestrogen alone, and other combinations of treatment. For women who used oestrogen both alone and with progestogen the number of person years in each category was determined by the date of switch.
The expected number of cases of endometrial neoplasia was obtained by multiplying the accumulated person years of follow up by the five year age specific incidence. These incidences were calculated from the 545 cases of endometrial neoplasia that had occurred from 1980 to 1983 inclusive in the background population (that is, not including the cases observed and person years accumulated in the cohort). An independent and blinded histopathological review of slides of tissue from 490 (90%) of the women with endometrial neoplasia in the background population and from all 107 in the cohort allowed diagnostic criteria to be standardised. Of the slides examined in the background population, 426 (87%) were classified as showing cancer and 64 (13%) as showing premalignant lesions (endometrial dysplasia with varying degrees of cellular atypia including carcinoma in situ") whereas in the cohort 74 (69%) slides showed cancer and 33 (31 %) premalignant lesions." ' Relative risk (the ratio of observed to expected cases) was used as the measure of association." Estimates of the number of person years in the total cohort were made from the randomly selected subcohort who had been sent questionnaires. To deal with the added variability in the estimation of the relative risk 95% confidence intervals were calculated according to a method developed for case-cohort studies using external comparisons, which took into account the variability in both the observed and expected numbers of cases. 6 To evaluate the possibility that the distribution of risk factors for endometrial cancer in the cohort was different from that in the background population a questionnaire study was also performed among 1240 women from the background population. '6 This did not show any differences in the prevalence of diabetes, hypertension, or nulliparity; the distribution of height and weight; or age at menarche and menopause. A higher proportion of the women who were prescribed oestrogen had a university education than did women in the background population (7 7% v 4 0%; p<0 05). In addition, oophorectomies and hysterectomies were four times and twice as common among the women given oestrogen than among the background population. The 
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1-4 (1 1 to 1-9) 1 9) ). There was evidence of a duration-response gradient, the relative risk estimates rising to 1*8 (1 1 to 3 2) in women exposed to oestrogen for longer than six years. Exposure to oestrogen solely in conjunction with progestogen did not increase the risk (relative risk 0 9 (0 4 to 2 0)). Nine of the women with endometrial cancer had taken oestrogen both alone and with progestogen: in five treatment with progestogen had been preceded by less than five years of oestrogen alone (relative risk 1 3 (0 5 to 3 6)) and in three by more than five years of oestrogen alone (relative risk 5 7 (0 1 to 249 7)), and in one treatment was in another pattern (relative risk 0 4 (0 1 to 3 2)). When premalignant lesions were considered as well, 107 cases of endometrial neoplasia were observed compared with 68 1 expected (relative risk 1 -6 (1-3 to 1-9)); among the women who did not take oestrogen 11 cases were observed compared with 7-9 expected (relative risk 1 4 (0 5 to 2 5)). Among women who had taken oestrogen similar patterns of risk were seen, but at slightly higher levels (table II). The relative risks for treatment with oestrogen alone were 1-7 (1 4 to 2 2) overall and 2-7 (1 8 to 4 2) after more than six years, whereas treatment with oestrogen solely in conjunction with progestogen was not associated with a significantly increased risk (relative risk 12 (0-6 to 2-1)). Treatment with oestrogen and progestogen was preceded by less than five years of treatment with oestrogen alone in six cases (relative risk 1 2 (0 5 to 3 0)) and by a longer period in four cases (relative risk 6-6 (0-2 to 285 9)). Two women had a different combination of treatment (relative risk 0 7 (0 2 to 2 9)).
The two outcomes (endometrial cancer only or all cases, including premalignant lesions) were analysed by type of oestrogenic compounds among women in the cohort who took oestrogen. Oestradiol compounds and conjugated oestrogens, when taken for more than three years without progestogen, were associated with a twofold to threefold increase in the risk of endometrial neoplasia, whereas other oestrogens were not (tables III and IV). 1-7(I 0to2-9) A duration-response relation was present with higher risk estimates when oestrogen had been taken for more than three years compared with shorter periods. Treatment with oestrogen alone resulted in an increased risk of neoplasia after less than three years' exposure to oestradiol and conjugated estrogens (relative risk [1] [2] [3] [4] [5] [6] [7] [8] (1-1 to 2-9) and 19 (1-0 to 3-4) respectively) ( 1toS5-6) ).
Discussion
The results of this study confirm an increase in the risk of endometrial cancer associated with a long duration of treatment with potent oestrogenic drugs, such as oestradiol and conjugated oestrogens, without concomitant progestogens. We found similar patterns and higher estimates of risk when premalignant lesions were included in the analysis. This study also provides preliminary evidence of the benefits of adding progestogen when oestrogens are given. No increase in risk was noted for women taking only such regimens, and there was a tendency for the women who had received mixed regimens (oestrogen treatment with and without progestogen) and who had a relatively longer duration of combined treatment, to have lower risks of endometrial neoplasia. Our data do not indicate, however, that added progestogen can prevent all endometrial neoplasia from developing in women treated with oestrogen. Furthermore, all the excess risk did not seem to be averted when progestogen was added if oestrogen alone had been used previously.
It must be recognised that in some instances-that is, for women given long term treatment with oestrogen and progestogen -the analyses were based on small numbers of cases and person years and therefore have wide confidence limits and limited statistical power. After the women who did not take the prescribed oestrogenic drugs or who had had hysterectomies and were thus not at risk of endometrial cancer were excluded from the cohort a study base of about 100 100 person years of follow up remained. This base gave more than a 90% chance of detecting an overall excess risk of twofold or greater, given two sided 95% confidence intervals and an average baseline incidence of 50/100 000.8 Among women exposed to any oestrogen compound for more than three years without added progestogen there was a 90% power to show an increased risk of threefold or greater, whereas among women given such long term treatment with oestrogen and progestogen the increase in risk would need to be fivefold or greater to be detected at this power. Thus the present study base did not provide adequate statistical power to reject the null hypothesis if there was an increased risk or to yield narrow confidence intervals if there was no increased risk among women given oestrogen with progestogen in the long term. The patterns of the risk estimates, however, consistently support there being no excess risk of endometrial cancer with such treatment. These are the first epidemiological data that pertain to the effects of oestrogens given with progestogen on the risk of endometrial neoplasia. Furthermore, the present results agree with the finding of short term clinical studies that cyclically added progestogen protects against the development of endometrial hyperplasia and atypical hyperplasia.4 As the follow up of the cohort continues the study base will be enlarged, leading to greater statistical power and allowing firmer conclusions to be drawn.
The blinded review of the histopathological specimens provided an unbiased diagnostic classification of the cases of endometrial neoplasia included in the analyses. All had been derived from a population based cancer register, in which 96% of cases among the cohort and in the background population had been reported and coded as cancers, the remaining 4% being coded as premalignant lesions. The review resulted in the reclassification as premalignant lesions of a substantially higher proportion of cancers among the cohort than the background population.'4 This is probably because most endometrial cancers that occur after exposure to oestrogen are found at an early clinical stage, are of a low grade, and are rarely more than superficially invasive into the myometrium'; in such cases it is difficult to establish firm morphological criteria for distinguishing between premalignant and malignant endometrial lesions.'3 Therefore, some of the cases classified as premalignant lesions might be regarded as cancers by other examiners. 14 Cases classified in the review as cancers were analysed separately from and together with those regarded as premalignant lesions. The results of both analyses agree with those from numerous retrospective case-control studies from the United States that report an increased risk of early endometrial cancer after two to four years of exposure to conjugated oestrogens given without progestogen.'
METHODOLOGICAL PROBLEMS
We used the case-cohort design to keep costs at a minimum while maintaining the basic advantages of a cohort study with efficient follow up through record linkage with a population based cancer register. None the less, some methodological problems could have affected the validity of the results.
Losses to follow up due to migration from the region were estimated by ascertaining the current domicile of a random sample of 742 of the 23 344 women, of whom 15 (2 0% of those still alive in 1988, five years after the end of the study) were no longer resident in the region. Assuming that this proportion of the entire cohort was lost to follow up after an average of three years of observation, we underestimated the observed outcome by no more than two cases.
Details of compliance with treatment, total duration of exposure to oestrogen, and the addition of progestogen among the entire cohort relied on data from questionnaires. The reliability of these exposure histories was checked against the available prescription forms during the three years for which prescriptions were collected and found to be satisfactory. '7 The details of treatment with oestrogen for all women from the cohort who had endometrial neoplasia were determined shortly after diagnosis, during the first five and a half years by a questionnaire administered in the hospital and later in the study by a posted questionnaire. Such unequal ascertainment of data could introduce a bias, but this is unlikely to have been substantial as the correlation between the duration of exposure reported on questionnaires and obtained from prescriptions was as good among these women (r=0-92) as among the sample from the cohort (r=0-98). 17 As 
CONCLUSIONS
We conclude that exposure to oestradiol compounds and conjugated oestrogens without concurrent progestogen is associated with an increasing risk of endometrial neoplasia with increasing duration of use (and latency of effect), with twofold to threefold increases in the risk after three or more years of use. The cyclical addition of progestogens for the greater part of the treatment may prevent or delay this increase in risk. Continuing follow up of the cohort is essential for further analyses, with enhanced statistical power, of the effects of recency, latency, and duration of the exposure to oestrogen on the risk of endometrial neoplasia.
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(Accepted 26 October 1988) ONE HUNDRED YEARS AGO ' [here seems to have of recent years been a considerable increase in the amount of alcohol consumed in the Belper Workhouse. The guardians having had their attention called to this, asked the medical officer for an explanation. This request called forth an amusing and spirited defence of the liberal prescription of alcoholic liquor to sick inmates. The medical officer declares that if there had not been this generous administration of intoxicants, the rates would have been reduced in two ways. There would have been a saving to the rates in the direct charge of the liquor used, and there would have been a saving by the premature removal of the poor people to "that bourne from whence no traveller returns."""They would die, and, in the words of the immortal Mr. Scrooge, 'materially reduce the surplus population.'" '[he medical officer insisted that his position was "unique in its impregnability." He gives, as the Hon. F. Strutt remarked at the meeting of the guardians, no statistics. A few cases, however, are narrated in proof of the necessity for alcohol. One case was that of a man brought in insensible from exposure. It does not appear to have occurred to the medical officer that there are other restoratives and restorative appliances besides alcohol. External heat, hot coffee or milk, or other liquid, aromatic spirit of ammonia, chloric ether, and compound cinnamon powder, have all been found useful in such conditions. Alcohol itself might be given in a medicinal mixture, or in such combinations as compound tincture of cardamoms, or simply in hot water. While we do not desire to question in the slightest the judiciousness of the prescriptions of intoxicants at Belper, and we are glad to note that the medical officer orders these remedies only to the sick, we cannot too strongly urge the utmost caution and deliberation in the therapeutic employment of beer, wine, and spirits in workhouses. There are so many abuses liable to arise where alcoholic drinks are freely ordered in institutions, that, wherever possible, other medicinal preparations ought to be preferred if as suitable for the case. In some very large workhouses and infirmaries very little liquor is consumed, and as no deleterious effect has been observed from the treatment on the rate of mortality, the very sparing employment of alcoholic intoxicants even as a medicine can be confidently commended to all engaged in the poor-law service. (British MedicalJournal 1889;i:31)
